JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wong, C W
Right arrow Articles by Leung, S Y
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wong, C W
Right arrow Articles by Leung, S Y
Journal of Clinical Pathology 2005;58:640-644
© 2005 BMJ Publishing Group Ltd & Association of Clinical Pathologists


ORIGINAL ARTICLE

BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs

C W Wong1, Y S Fan1, T L Chan1, A S W Chan1, L C Ho2, T K F Ma3 the Cancer Genome Project4, S T Yuen1, S Y Leung1

1 Department of Pathology, University of Hong Kong, Queen Mary Hospital, Hong Kong
2 Department of Pathology, Queen Elizabeth Hospital, Hong Kong
3 Department of Pathology, Alice Ho Mui Ling Nethersole Hospital, Hong Kong
4 Cancer Genome Project, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK

Correspondence to:
Dr S Y Leung
Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong; suetyi{at}hkucc.hku.hk Background: Malignant melanoma arising from different body compartments may be associated with differing aetiological factors and clinical behaviour, and may manifest diverse molecular genetic profiles. Although many studies have focused on cutaneous melanoma, little is known of mucosal and other types of melanoma. In particular, malignant melanoma of soft parts is different from other melanomas in many respects, yet manifests a common melanocytic differentiation. Mutation of BRAF is now known to be common in cutaneous melanomas, and raises possible new therapeutic options of anti-RAF treatment for these patients. Few data are available for non-cutaneous melanomas.

Aims: To study the incidence of BRAF and NRAS mutations in melanomas arising in diverse internal organs.

Methods: Fifty one melanomas from various internal organs were investigated for BRAF and NRAS mutation by direct DNA sequencing.

Results: BRAF and NRAS mutations were found in two and five mucosal melanomas arising from the aerodigestive and female genital tracts (n = 36). Their occurrence is mutually exclusive, giving a combined mutation incidence rate of 19.4% in mucosal melanomas. Both BRAF and NRAS mutations were absent in malignant melanoma of soft parts (n = 7). BRAF mutation was also absent in uveal melanoma (n = 6), but was seen in two of five cutaneous melanomas. The incidence of BRAF or combined BRAF/NRAS mutations in all non-cutaneous groups was significantly lower than published rates for cutaneous melanomas.

Conclusion: Each melanoma subtype may have a unique oncogenetic pathway of tumour development, and only a small fraction of non-cutaneous melanomas may benefit from anti-RAF treatment.


Abbreviations: MAPK, mitogen activated protein kinase; PCR, polymerase chain reaction; UV, ultraviolet

Keywords: BRAF; NRAS; mucosal melanoma; malignant melanoma of soft parts




This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
M. P. Quinlan, S. E. Quatela, M. R. Philips, and J. Settleman
Activated Kras, but Not Hras or Nras, May Initiate Tumors of Endodermal Origin via Stem Cell Expansion
Mol. Cell. Biol., April 15, 2008; 28(8): 2659 - 2674.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Benvenuti, A. Sartore-Bianchi, F. Di Nicolantonio, C. Zanon, M. Moroni, S. Veronese, S. Siena, and A. Bardelli
Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti-Epidermal Growth Factor Receptor Antibody Therapies
Cancer Res., March 15, 2007; 67(6): 2643 - 2648.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Saldanha, L. Potter, P. DaForno, and J. H. Pringle
Cutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation Frequencies
Clin. Cancer Res., August 1, 2006; 12(15): 4499 - 4505.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.